High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Co-operative Oncology Group study

Απλή σελίδα τεκμηρίου
dc.contributor.authorFountzilas, G.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorPavlidis, N. A.en
dc.contributor.authorMakrantonakis, P.en
dc.contributor.authorTsavaris, N.en
dc.contributor.authorKalogera-Fountzila, A.en
dc.contributor.authorGiannakakis, T.en
dc.contributor.authorBeer, M.en
dc.contributor.authorKosmidis, P.en
dc.date.accessioned2015-11-24T19:13:40Z
dc.date.available2015-11-24T19:13:40Z
dc.identifier.issn0300-8916-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21212
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBreast Neoplasms/*drug therapyen
dc.subjectDrug Administration Scheduleen
dc.subjectDrug Evaluationen
dc.subjectEpirubicin/*administration & dosage/adverse effectsen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectRemission Inductionen
dc.titleHigh-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Co-operative Oncology Group studyen
heal.abstractFifty-two women with advanced breast cancer were treated with 6 cycles of epirubicin. Even though the study was started with a dose schedule of 110 mg/m2 every 3 weeks, the average treatment interval was 26 days and the median weekly dose 78% of the protocol requirement. Forty-eight patients were evaluable for response; 3 achieved a complete remission which lasted for 17, 24 and 65 weeks, respectively, and 14 a partial remission. Median survival was 32 weeks. Toxicity included nausea/vomiting (68%), anemia (24%), leukopenia (37%), thrombocytopenia (8%), alopecia (81%), stomatitis (24%), diarrhea (14%), fever (19%) and fatigue (14%). Also 1 treatment-related death occurred and 2 cases of arrhythmia. Monotherapy with high doses of epirubicin has definite activity in advanced breast cancer and deserves further study in combination with hematopoietic growth factors which might allow a higher dose intensity.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/1862551-
heal.journalNameTumorien
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1991-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ